How Doctor Care Anywhere Is Driving 7.5% Consultation Growth Amid Cashflow Turnaround
Doctor Care Anywhere reports a 7.5% rise in consultations excluding secondary care and sustains positive cashflow for the second consecutive quarter, reaffirming ambitious medium-term growth targets.
- 7.5% year-on-year consultation growth excluding secondary care
- Activated lives increased 11.2% to 1.2 million
- Second consecutive quarter of positive net operating and investing cash inflow (£0.6m)
- Launch of new digital pathways in Mental Health, Musculoskeletal, and Skin Cancer care
- Medium-term guidance reaffirmed – revenue doubling to £76m and 15% EBITDA margin
Consultation Growth and Platform Engagement
Doctor Care Anywhere Group PLC has reported a solid quarter ending September 2025, with consultations rising 7.5% year-on-year when excluding secondary care appointments. This growth was supported by new service offerings and enhancements to its telehealth platform, reflecting increased patient engagement. Activated lives, the number of users signed up to the service, rose 11.2% to 1.2 million, underscoring the company’s expanding reach in the UK private telehealth market.
While there was a slight seasonal dip quarter-on-quarter in activated lives and consultations, repeat patients accounted for 74% of consultations, up both sequentially and annually, indicating growing patient loyalty and satisfaction with the platform.
Financial Performance and Cashflow Strength
Financially, Doctor Care Anywhere sustained positive momentum with a net operating and investing cash inflow of £0.6 million (A$1.2 million) in Q3 2025. This marks the second consecutive quarter of positive cash generation, a notable turnaround from a £0.9 million outflow in the same quarter last year. The company ended the quarter with a robust cash balance of £5.4 million (A$11.0 million), providing a solid foundation for further investment in growth initiatives.
The year-on-year improvement was driven by higher customer receipts, reduced operating and staff costs, and productivity gains. The quarter-on-quarter decline in cash inflow was attributed to timing effects, including a large customer catch-up payment and annual subscription fees recorded in the previous quarter.
Strategic Product Expansion and Operational Efficiency
Doctor Care Anywhere has expanded its clinical offerings with new digital treatment pathways in Mental Health, Musculoskeletal, and Skin Cancer care. These pilots are live and set for rapid rollout, aiming to differentiate the company’s patient-centred care at lower costs. Additionally, the company is developing digital-first products in weight management and preventive health assessments, targeting multiple channels including direct-to-consumer and corporate programs, with launches expected in Q4 2025.
Operationally, the company continues to streamline its model following a transformation in the first half of the year. Cost reductions and efficiency improvements are translating into tangible benefits for patients and clients while freeing resources to fuel growth.
Medium-Term Outlook and Capital Structure
Management reaffirmed its medium-term guidance presented earlier in 2025, targeting revenue growth to £76 million (A$156 million) within 3 to 5 years, effectively doubling from 2024 levels, and achieving a 15% EBITDA margin. This implies a compound annual growth rate exceeding 12%, signaling confidence in the company’s strategic direction and market opportunity.
On the capital front, Doctor Care Anywhere holds £10.6 million (A$21.6 million) in convertible loan debt maturing in January 2028, carrying zero coupon interest, which provides financial flexibility as the company invests in innovation and market expansion.
Bottom Line?
With sustained cashflow and strategic product launches, Doctor Care Anywhere is poised to accelerate growth, but seasonal fluctuations and competitive pressures remain key watchpoints.
Questions in the middle?
- How will the new digital pathways impact patient acquisition and retention in the coming quarters?
- What are the risks and opportunities associated with the upcoming weight management and preventive health products?
- How might the convertible loan maturity in 2028 influence the company’s capital strategy and shareholder value?
